Highlights Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Real-time Estimate Cboe BZX Other stock markets 12:06:50 2024-04-29 pm EDT			5-day change	1st Jan Change
94.14 ^USD	+1.22%		+3.71%	+1.88%

Apr. 25	Transcript : Blueprint Medicines Corporation - Special Call
Mar. 22	Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	Feb. 23	CI
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	Feb. 22	CI
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	Feb. 15	MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	Feb. 15	MT
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q4 Revenue $72M, vs. Street Est of $67.1M	Feb. 15	MT
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024	Feb. 15	CI
Blueprint Medicines Receives European Approval for Ayvakyt in Indolent Systemic Mastocytosis	Dec. 12	MT
Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis	Dec. 12	CI
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted At 2023 Ash Annual Meeting	Dec. 09	CI
Blueprint Medicines Gets Positive CHMP Opinion For Indolent Systemic Mastocytosis	Nov. 10	MT
Blueprint Medicines' Ayvakyt (Avapritinib) Receives Positive Chmp Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis	Nov. 10	CI
Blueprint Medicines' Shares Surge After Better-Than-Expected Q3 Results	23-10-26	MT
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q3 Revenue $56.6M, vs. Street Est of $50.7M	23-10-26	MT
Blueprint Medicines Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Qiagen Says FDA Authorized Companion Diagnostic for Gastrointestinal Stromal Tumors Therapy	23-08-08	MT
Blueprint Medicines' Shares Fall After Reporting Narrowed Q2 Net Loss, Higher Revenue	23-08-02	MT
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q2 Revenue $57.6M, vs. Street Est of $45.6M	23-08-02	MT
Blueprint Medicines Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Blueprint Medicines Announces Clinical Data for Multiple Programs Across its Precision Therapy Portfolio at the 2023 American Society of Clinical Oncology	23-06-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Highlights

Filters